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Twisted gastrulationBone morphogenetic proteins (BMPs), as well as the BMP-binding molecules Chordin (Chd), Crossveinless-2
(CV2) and Twisted Gastrulation (Tsg), are essential for axial skeletal development in the mouse embryo. We
previously reported a strong genetic interaction between CV2 and Tsg and proposed a role for this
interaction in the shaping of the BMP morphogenetic ﬁeld during vertebral development. In the present
study we investigated the roles of CV2 and Chd in the formation of the vertebral morphogenetic ﬁeld. We
performed immunostainings for CV2 and Chd protein on wild-type, CV2−/− or Chd−/− mouse embryo
sections at the stage of onset of the vertebral phenotypes. By comparing mRNA and protein localizations we
found that CV2 does not diffuse away from its place of synthesis, the vertebral body. The most interesting
ﬁnding of this study was that Chd synthesized in the intervertebral disc accumulates in the vertebral body.
This relocalization does not take place in CV2−/−mutants. Instead, Chd was found to accumulate at its site of
synthesis in CV2−/− embryos. These results indicate a CV2-dependent ﬂow of Chd protein from the
intervertebral disc to the vertebral body. Smad1/5/8 phosphorylation was decreased in CV2−/−vertebral
bodies. This impaired BMP signaling may result from the decreased levels of Chd/BMP complexes diffusing
from the intervertebral region. The data indicate a role for CV2 and Chd in the establishment of the vertebral
morphogenetic ﬁeld through the long-range relocalization of Chd/BMP complexes. The results may have
general implications for the formation of embryonic organ-forming morphogenetic ﬁelds.De Robertis).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Cells do not exist in isolation but rather develop in ﬁelds of
hundreds or thousands of cells in which interactions with their
neighbors determines differentiation, cell division or death. This is
illustrated by the primary embryonic ﬁeld of the Xenopus gastrula,
which can be cut in half, so that each half can regenerate and form an
identical twin (Spemann, 1938; De Robertis, 2009). This ability to self-
regulate indicates that cells within the ﬁeld must be in communica-
tion with each other over considerable distances. The early embryonic
ﬁeld is called the primary ﬁeld. Later in development, secondary
morphogenetic ﬁelds, such as eye, lens or the limb ﬁelds are formed
(Huxley and De Beer, 1934; Eivers et al., 2008). This principle was
discovered by Ross Harrison (1918), who transplanted half of the
mesodermal forelimb ﬁeld into the ﬂank of a host salamander embryo
and obtained the formation of a complete limb. Understanding how
ﬁelds of cells communicate over long distances is a crucial question in
developmental biology.
Positional information is provided to cells by the action of
extracellular molecules designated morphogens by Türing (1952),which can form spatial gradients in tissues. The formation of a gradient
and the local concentration and activity of the morphogen is regulated
by a plethora of extracellular factors, which have been best studied in
theDrosophila, Xenopus and zebraﬁsh dorso-ventral (D-V) BMPprimary
embryonic ﬁeld (Little and Mullins, 2006; O'Connor et al., 2006; De
Robertis, 2009; Umulis et al., 2009). BMPs constitute a family of
morphogens essential during embryogenesis and organogenesis, which
are regulated by interactions with secreted BMP-binding molecules
such as Chd, Chd-like-1 (Chdl-1), Chd-like-2 (Chdl-2), Noggin, Tsg and
CV2 (Zakin and De Robertis, 2010).
It has been recently demonstrated that in the frog gastrula BMPs can
ﬂow from the dorsal Spemann's organizer to the ventral-most regions
of the embryo and that, importantly, this ﬂux of BMPs requires Chd
(Ben-Zvi et al., 2008; Plouhinec andDeRobertis, 2009). Chd is a secreted
protein containing four cysteine-rich (CR)domains,whichmediate BMP
binding and prevent interaction with BMP receptors (BMPRs) (Piccolo
et al., 1996; Larrain et al., 2000), whichmediate the anti-BMP activity of
Chd. Chd itself is regulated by the Tolloid family of extracellular zinc
metalloproteinases which can degrade Chd through cleavage at two
speciﬁc sites (Piccolo et al., 1997). Chdl-1 (Cofﬁnier et al., 2001;
Nakayama et al., 2001; Sakuta et al., 2001) and Chdl-2 (Nakayama et al.,
2004; Zhanget al., 2007) are structurally and functionally similar toChd,
but contain three CR BMP-binding domains instead of four. Tsg is a
secreted protein that binds to BMP aswell as to Chd, Chdl-1 and Chdl-2,
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Tolloid protease (Oelgeschläger et al., 2000; Larrain et al., 2001; Scott
et al., 2001; Nosaka et al., 2003; Little and Mullins, 2004; Nakayama
et al., 2004; Petryk et al., 2004; Zakin and De Robertis, 2004). Upon
cleavage of Chd by Tolloid, BMPs are released from ternary BMP/Tsg/
Chd complexes, allowingpreviously sequesteredBMPs to signal (Piccolo
et al., 1997; Larrain et al., 2001).
Another important player in the BMP network is CV2, which was
ﬁrst identiﬁed in Drosophila to be required for the formation of wing
crossveins (Conley et al., 2000). These structures require high BMP
levels (Blair, 2007), suggesting that CV2 functions to enhance BMP
signaling. Homologs of CV2 have since been isolated in vertebrates
(Cofﬁnier et al., 2002) and both pro and anti-BMP effects have been
described (Binnerts et al., 2004; Coles et al., 2004; Ikeya et al., 2006;
O'Connor et al., 2006; Zhang et al., 2008). CV2 is a secreted molecule
that contains ﬁve Chordin-like CR modules that bind BMPs, inhibiting
signaling (Zhang et al., 2008). CV2 also displays a carboxy-terminal
von Willebrand Factor type D (vWFd) domain containing a heparin
binding site which binds to cell surface heparan sulfate proteoglycans,
greatly limiting CV2 diffusion (Rentzsch et al., 2006; Serpe et al.,
2008). Vertebrate CV2 is not degraded by Tolloid metalloproteinases
(Ambrosio et al., 2008). Serpe et al. (2008) proposed a model to
explain the dual activities of CV2. CV2 binds to BMPR Thickveins
(Tkv), acting as a co-receptor, so that at high concentrations CV2
inhibits BMP signaling while at low concentrations it acts to facilitate
BMP signaling (Umulis et al., 2009). CV2 is able to clear BMP4 from the
extracellular space by triggering endocytosis (Kelley et al., 2009).
In the ﬂy pupal wing, genetic mosaic studies have shown that CV2
is expressed in the crossvein where it serves to increase signaling by
Dpp, a protein homologous to vertebrate BMP2/4, which is expressed
in the longitudinal veins. In the intervein regions, pupal wing cells
express large amounts of Short gastrulation (Sog), the homolog of
Chd. Ralston and Blair (2005) have proposed that a signaling system
based on extracellular ﬂow of BMP, analogous to that of the early
Drosophila embryo, may exist during pupal wing patterning. Other
mutations that cause crossveinless phenotypes identical to CV2
include Tolloid-related metalloproteinase (Tlr, also known as Tolkin)
(Ralston and Blair, 2005) and the Drosophila Twisted gastrulation 2
(Tsg-2) protein (Shimmi et al., 2005a; Vilmos et al., 2005), which was
the ﬁrst crossveinless mutation discovered (Bridges, 1920), and is
called cv or cv-1. The hypothesis is that complexes of Dpp/dTsg-2/Sog
could become concentrated in the crossvein region, in which active
Dppmade in distant vein regions would be released by cleavage by Tlr
(Blair, 2007).
We have proposed amolecular mechanism for the pro-BMP effects
of CV2 inwhich this protein acts as a sink for the ﬂow of Chd/Tsg/BMP
complexes towards the ventral side of the Xenopus gastrula (Ambrosio
et al., 2008). CV2 is expressed in the ventral side, where BMP signaling
is highest. Biochemical studies showed that CV2 binds with high
afﬁnity (dissociation constant, KD, of 1 to 2 nM) to Chd, and with even
higher afﬁnity to Chd/BMP complexes or Chd fragments generated
after cleavage by Tolloid (Ambrosio et al., 2008). In this model, CV2
concentrates Chd/Tsg/BMP complexes in the ventral side, where BMP
can be released for signaling by Tolloid cleavage of Chd to achieve
peak signaling levels (De Robertis, 2009, Lee et al., 2009).
Inactivation of CV2 in the mouse is lethal at birth and CV2−/−
neonates present skeletal abnormalities, in particular the loss of
cartilage and bone in the vertebral bodies (Ikeya et al., 2006; Zakin
et al., 2008; Kelley et al., 2009). Chd−/− mice also have reduced
vertebral bodies (Bachiller et al., 2003; Supplementary Fig. 1). CV2
mRNA is expressed in prospective vertebral body cartilage, while Tsg,
Chd, Chdl-1, Chdl-2, Bmp4 and Tolloid-like1 (Tll-1/BMP1) mRNAs are
transcribed in the prospective intervertebral discs (Zakin et al., 2008).
An intriguing observation was that in CV2 mutants the C-terminal
phosphorylation of Smad1/5/8, a measure of BMP signaling activity,
was decreased in the intervertebral disc at a considerable distancefrom the prospective vertebral body in which CV2 is expressed (Zakin
et al., 2008). Since CV2 was expected to have mostly local effects
(Serpe et al., 2008), this long-range effect prompted us to investigate
this phenomenon further.
In the present study, we analyzed the distribution of CV2 and Chd
proteins, and compared them with that of their respective mRNAs.
CV2 protein remained localized to the prospective vertebral body,
where its mRNA is expressed. Surprisingly, Chd mRNA was tran-
scribed in the prospective intervertebral disc, yet its protein
accumulated in the prospective vertebral body. Knowing from
biochemical studies that CV2 binds Chd (Ambrosio et al., 2008), we
examined the distribution of Chd protein in CV2 mutant mice. We
found that CV2 is required for the relocalization of Chd from the
prospective intervertebral disc to the prospective vertebral body
cartilage. We propose that the ﬂow of growth factors and their
antagonists may be a general feature of the organ-forming secondary
morphogenetic ﬁelds described in the embryological literature.
Materials and methods
CV2 and Chd mutant mice and crosses
The CV2 and Chd mutant strains were previously described
(Bachiller et al., 2000; Zakin et al., 2008) and maintained in the
B6SJLF1/J hybrid background (Jackson Laboratories). The Chd strain
used was the original isolate, which lacks the recently described
secondary mutation in Tbx1 (Choi and Klingensmith, 2009) utilized in
other studies (Bachiller et al., 2003; Delot et al., 2007). The CV2 and
Chd mutant strains are publicly available from Jackson Laboratories
through an agreement made possible by the Howard Hughes Medical
Institute (http://jaxmice.jax.org; stock numbers are 007552 for Chd
and 007554 for CV2). We generated wild-type, CV2−/−, and Chd−/−
homozygous embryos by crossing CV2+/− and Chd+/− heterozygous
animals. The embryos were collected at 12.5 d.p.c., ﬁxed in 4%
paraformaldehyde in PBS, dehydrated, embedded in parafﬁn, and
serially sectioned at either 5 μm or 10 μm.
Genotyping
Genotyping of the CV2mutant strainwas performed by PCR using the
following primers: pGN1 (5'ACC CTC TGT GTC CTC CTG TTA A3'),
3'CV2down (5'AGT CTC CTC CTA TGT TTC TTG C3'), CV2wtup (5'GCC AAG
CCT GTG AGT CTT TC3'), and CV2wtdown (5'ACT TAC AGGGGTGGA TGC
AG3'), as previously described (Zakin et al., 2008). Genotyping of the Chd
mutant strain was performed by PCR using the following primers: Neo2
(5'GTT CCACATACACTTCATTCTCAG3'), Null Low(5'GGTAGGAGACAG
AGAAGCGTAAAC T3'), Null Up (5'GAG TTA GGAGGTGGAGCT CTA CAC
T3'), as previously described (Bachiller et al., 2000).
In situ hybridization and histology
Procedures for in situ hybridization on parafﬁn sections were as
described (http://www.hhmi.ucla.edu/derobertis/), using the following
probes: CV2 (Cofﬁnier et al., 2002), Chd (Bachiller et al., 2000) and BMP4
(Winnier et al., 1995) on 10 μm sections. Hematoxylin and eosin (H&E)
stainingswere as described (Zakin andDe Robertis, 2004) and performed
on either 5 μm (Figs. 1 and 2) or 10 μm sections (Figs. 3 and 6). For H&E
staining of previously immunostained sections, slides were placed
obliquely in a Coplin jar containing Xylene to allow the coverslip to fall
off. Subsequent procedures are as for standard H&E stainings.
Immunohistochemistry
Commercial anti-CV2 (R&D AF2299), anti-Chd (R&D AF758) and
anti-BMP4 (Chemicon Millipore MAB1049) antibodies were used at a
1:50 dilution and anti-pSmad1 (Cell Signaling 9511 L) was used at
Fig. 1. Chd protein concentrates in the prospective vertebral bodies. (A) Sagittal section of a Wild-type 12.5 d.p.c. mouse embryo stained with Chd antibody and then counterstained
with H&E. (B) Sagittal section of a 12.5 d.p.c. Chd−/−mouse embryo similarly stained. (C) Chd antibody staining on wild-type embryo, showing Chd protein localized in prospective
vertebral body. (D) No signal is detected on Chd−/−mouse embryo section, using Chd antibody thus showing that the Chd antibody is speciﬁc (n=2 Chd−/− embryos, with similar
results). (E) Magniﬁed view of boxed area in (C) showing Chd staining in vertebral bodies C2 through C4. (F) Same section as in (E) counterstained with H&E. C2–C4, cervical
vertebrae; ivd, prospective intervertebral disc; vb, prospective vertebral body.
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jar containing boiling (i.e., previously brought to a boil in a microwave
oven) 10 mM sodium citrate, pH 6 for a total of 40 min at room
temperature. For Chd antibody staining, a reducing step was included
to improve protein denaturation (sections are reduced with 4 mM
DTT for 1 h at room temperature, followed by 500 mM iodoacetate for
30 min at 37 °C to block sulfhydryl groups). After incubation with
biotinylated secondary antibody, two ampliﬁcation steps were added
to improve detection threshold using the ABC reagent (Vector Labs
PK4001) and the TSA biotin system (Perkin Elmer NEL700A). A
detailed protocol of this improved immunostaining procedure is
available at http://www.hhmi.ucla.edu/derobertis.Western blot analyses
Cos7 cells were transfectedwith 2 μg per 6-well plate of full-length
mouse CV2 cDNA cloned into pCS2, or pCS2 empty vector using
Fugene HD (Roche). Samples were solubilized in RIPA lysis buffer
(50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X100, 0.5%Na Deoxycholate, 0.1% SDS) containing protease inhibitors (Complete
tablets, Roche) or directly in electrophoresis loading buffer. Recom-
binant mouse Chd (R&D systems #758-CN-050) was diluted to 5 nM
in serum-free medium. Anti-αTubulin (1:1000, Calbiochem #CP06),
anti-mChd (1:250, R&D systems #AF758) and secondary antibodies
anti-mouse IRDye 680CW (1:1000 Licor) and anti-goat IRDye 800CW
(1:1000, Licor) were used for Western blot analyses, and signals
detected using a Licor Odyssey infrared imager.Quantiﬁcation of pSmad1/5/8 signal in vertebral bodies
Images of immunostained sections were acquired using a Zeiss
microscope and Axiovision software under identical exposure condi-
tions. The brown pSmad1/5/8 signal was extracted using a deconvolu-
tion algorithm (Ruifrok and Johnston, 2001; http://www.dentistry.
bham.ac.uk/landinig/software/cdeconv/cdeconv.html) with the Ima-
geJ software (http://rsbweb.nih.gov/ij/). For image histograms, back-
ground levels from sections immunostained with secondary antibody
only were subtracted, and the region corresponding to the vertebral
Fig. 2. CV2 mRNA is transcribed in the prospective vertebral bodies, while Chd and BMP4 mRNAs are expressed in the prospective intervertebral discs. In situ hybridizations and H&E
staining were performed on adjacent sagittal sections of the same 12.5 d.p.c. wild-type mouse embryo. (A) CV2 in situ hybridization, showing CV2 mRNA localized in the prospective
vertebral bodies. (B) Magniﬁed view of area boxed in (A) showing CV2 staining in thoracic vertebrae (T) 2 through 4. (C) Chd in situ hybridization showing Chd mRNA expressed in
prospective intervertebral disc. (D) Magniﬁed view of area boxed in (C) showing ChdmRNA expression. (E) BMP4 in situ hybridization showing BMP4mRNA expression in prospective
intervertebral discs. (F)Magniﬁedviewof areaboxed in (E) showingBMP4mRNAstaining. (G)H&E stainingona section adjacent to theone shown in(E). (H)Magniﬁedviewof areaboxed
in (G) showing regions of lowandhigh tissuedensity corresponding to theprospective vertebral body and intervertebral disc, respectively. Thebars inB,D and F indicate thedistance in μm
between the intervertebral disc and the center of the vertebral body.
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inside this area were selected as corresponding to pSmad1 signal when
their values exceeded background levels. The normalized amount of
pSmad1 signal was considered to be the number of these pixels dividedby the number of nuclei in the selected region as counted on H&E
sections. Calculations were performed on three vertebrae per histolog-
ical section in two independent experiments. The result is presented as
the ratio of nuclear pSmad1/5/8 in CV2−/− compared to wild-type.
Fig. 3. Chd mRNA is synthesized in the prospective intervertebral disc while Chd protein accumulates in the prospective vertebral bodies, in which CV2 mRNA and protein are also
found. In situ hybridizations and immunostainings were performed on adjacent sagittal sections of a 12.5 d.p.c. wild-type mouse embryo. (A) Chd antibody staining showing Chd
protein localized to the prospective lumbar (L) vertebral bodies. (B) Chd in situ hybridization in adjoining section showing ChdmRNA expressed in prospective intervertebral discs.
(C) Merged image of panels (A) and (B), showing that ChdmRNA and Chd protein are localized in complementary regions. Chd protein accumulates at a considerable distance from
where it is synthesized. Note also that Chd accumulates predominantly in the posterior half of the vertebral body at this lumbar level. (D) CV2 antibody staining showing CV2 protein
localized in the prospective vertebral body. (E) CV2 in situ hybridization showing CV2mRNA localized in the prospective vertebral body. (F) Merged images showing that CV2mRNA
and CV2 protein co-localize. The secreted CV2 protein does not diffuse far from its site of synthesis. n, notochord.
208 L. Zakin et al. / Developmental Biology 347 (2010) 204–215Results
CV2 and Chd proteins are localized in the prospective vertebral bodies
Because both CV2 and Chd mutants had phenotypes in the axial
skeleton, we decided to study the localization of CV2 and Chd proteins on
sagittal parafﬁn sections of 12.5 d.p.c. wild-type embryos. At this stage,
vertebralmaturation is easily observed ina cranio-caudal sequence, and is
the stage at which mutant phenotypes are ﬁrst observed. Antibody
speciﬁcity was assessed through staining of CV2 and Chd homozygous
mutant embryo sections with anti-CV2 and anti-Chd antibodies,
respectively. As expected, the anti-Chd (Fig. 1A–D) and anti-CV2
(Supplementary Fig. 2) antibodies did not show any cross-reaction on
their respective mutants. Sections were counterstained with H&E to
reveal morphology; the prospective vertebral body can be recognized by
its lower cellular density compared to the prospective intervertebral disc.
Immunostaining with anti-CV2 antibody on wild-type embryo
sections showed that CV2 protein is localized to the prospectivevertebral body (Supplementary Fig. 2). To our surprise, anti-Chd
antibody staining on wild-type embryo sections was also mainly
localized in the prospective vertebral body (Fig. 1E, F).
The localization of CV2 protein to the prospective vertebral body is
consistent with work in Drosophila (Serpe et al., 2008) showing that
CV2 does not diffuse further than two cell diameters, as it is tethered
to the cell membrane by the glypican Dally. In the mouse, it has been
shown that BMP signaling is required in the prospective vertebral
body cartilage (Yoon et al., 2005; Retting et al., 2009) for vertebral
cartilage development. The observation that was unexpected was the
detection of Chd protein accumulation in the prospective vertebral
body. This is because ChdmRNA had been described to be transcribed
in the intervertebral disc (Zakin et al., 2008). This ﬁnding was
consistent with the idea that Chd protein facilitates the ﬂow of BMPs
to distant sites where their signaling is required (Piccolo et al., 1997;
Eldar et al., 2002; Shimmi et al., 2005a,b; Wang and Ferguson, 2005;
Ben-Zvi et al., 2008), which in the case of the mouse vertebral column
would correspond to the prospective vertebral body.
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towards regions of high CV2 expression?
We ﬁrst re-examined the localization of CV2, Chd and BMP4
mRNAs by in situ hybridization on adjacent serial parafﬁn sections of
wild-type 12.5 d.p.c. embryos. We found CV2mRNA was expressed in
the prospective vertebral body (Fig. 2A, B), while Chd (Fig. 2C, D) and
BMP4 (Fig. 2E, F) mRNAs were transcribed in the prospective
intervertebral region of the developing vertebral column. Although
the expression of all BMPs was not analyzed here, BMP2 and BMP7
mRNAs are also expressed in the prospective intervertebral region
(Lyons et al., 1995, and data not shown).Within the detection levels of
in situ hybridization, Chd and BMP4were not found to be expressed in
prospective vertebral bodies. Staining of an adjacent section with H&E
(Fig. 2G, H), which better reveals the morphology of the vertebral
column with the vertebral segments divided into condensed
(intervertebral disc) and uncondensed regions (vertebral body),
helped to unambiguously identify the regions where the mRNAs
were expressed.Fig. 4. The localization of CV2 is independent of Chd. Immunostainings with a CV2 antibod
embryos. (A) CV2 antibody staining on a wild-type section, showing the presence of CV2 in th
in the prospective vertebral bodies of cervical vertebrae C1 through C6. (C) CV2 antibody sta
vertebral column. (D) Higher-power view of area boxed area in (C) showing staining of CV2
animal, CV2 staining was stronger than wild-type (compare panels A and C); however, this
was undetectable on a CV2−/− section, demonstrating the speciﬁcity of the antibody. (F) MBecause thedifferentiation of thevertebral column is dynamic, itwas
important to study the proteins compared to their mRNAs within the
same embryo. Therefore, we compared the localization of Chd and CV2
proteins to that of their mRNAs in adjoining sections. As before, Chd
proteinwaspresent in theprospective vertebral body, butwe alsonoted
a higher concentration of the protein in the posterior half of each
prospective vertebral body (Fig. 3A), particularly in more immature
lumbar vertebrae (see also posterior segments in Fig. 1C). In situ
hybridization using a Chd probe on the same embryo showed the Chd
mRNA localized to the prospective intervertebral disc (Fig. 3B). The
merging of the two images clearly showed that Chd protein and Chd
mRNA are found mainly in complementary regions (Fig. 3C). This
ﬁnding is consistent with the proposed ﬂow of Chd protein from the
prospective intervertebral region, where it is synthesized, to the future
vertebral body, where the Chd protein accumulates (Fig. 3C). Because
Chd was found to be more concentrated in the posterior half of the
vertebral body, this suggested that Chdmay ﬂow towards the vertebral
body in a posterior to anterior direction, although this remains to be
demonstrated. This preferential accumulation of Chd in the posteriory performed on sagittal sections of 12.5 d.p.c. wild-type, Chd−/− and CV2−/− mouse
e prospective vertebral body. (B) Magniﬁed view of area boxed in (A) showing staining
ining is normal in Chd−/− embryos. The basioccipital bone is also stained anterior to the
in C1 through C6 similar to that of the wild-type embryo in panel (B). In this Chd−/−
difference was not observed in two other mutants analyzed. (E) CV2 antibody staining
agniﬁed view of boxed area in (E).
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marked at thoracic levels (Fig. 5B below).
CV2 protein was found in the prospective vertebral body (Fig. 3D).
In situ hybridization on an adjacent section of the same embryo
indicated co-localization of CV2 mRNA and protein (Fig. 3E). Merged
images conﬁrmed that CV2 protein does not diffuse from its site of
synthesis (Fig. 3F). Since physical binding between CV2 and Chd had
been detected biochemically (Ambrosio et al., 2008), these results
prompted the next question: does CV2 play a role in determining the
localization of Chd protein in vivo?
CV2 is required for the localization of Chd in the prospective vertebral
body
To test whether a possible interaction between CV2 and Chd was
responsible for the relocalization of Chd from its site of synthesis in
the prospective intervertebral disc towards the prospective vertebral
body, we performed immunohistochemistry on parafﬁn sections of
wild-type, CV2−/−, and Chd−/− mouse embryos. CV2 protein was
found in the prospective vertebral body of wild-type (Fig. 4A, B) and
Chd−/− mutant sections (Fig. 4C, D) but not in control CV2−/−
sections (Fig. 4E, F). This control experiment demonstrated that CV2
does not require Chd for its proper localization.
Chd protein was localized to the prospective vertebral body in wild-
type embryos (Fig. 5A, B). When sections of CV2−/− embryos were
stained in parallel, no accumulation of Chd was found in the vertebral
body region (Fig. 5C, D). Instead, Chd protein was detectable only in the
intervertebral disc of CV2 mutants, where it accumulated at higher
levels than in thewild-type (compare Fig. 5B to D, see arrows). The total
levels of Chd accumulated did not reach the levels found in vertebral
bodies in the wild-type, presumably because of degradation of Chd by
Tolloid metalloproteinases. In situ hybridization experiments showed
that Chd mRNA is synthesized in the intervertebral discs, but not in
vertebral bodies, of both wild-type and CV2−/− mice (Supplementary
Fig. 3). In wild-type embryos, Chd protein accumulates in the
extracellular matrix of developing vertebral bodies (compare Figs. 1EFig. 5. In the mouse embryo, Chd protein requires CV2 for its accumulation in the prospectiv
with a Chd antibody and H&E staining performed on sagittal sections of 12.5 d.p.c. wild-typ
accumulation of Chd in prospective vertebral bodies (vb). (B) Magniﬁed view of area bo
accumulation is not detectable in vertebral bodies in the absence of CV2. (D) Magniﬁed vie
prospective vertebral bodies; this result was observed in 4 different CV2 mutant embryos (8
overexpression of a full-length CV2 construct in Cos7 cells does not stabilize added recombi
were collected at different time points; α-tubulin was used as a loading control. Note that CV
cells and extracellular matrix) or culture medium from Cos7 cells minus or plus CV2 overexp
of recombinant Chd protein, CV2 is able to sequester Chd.and 5B to the histological images in Figs. 1F and 6A). Similarly, CV2
proteinwas found in the extracellularmatrix, rather than on the surface
of vertebral body cells (Supplementary Figs. 2F, H). We conclude that
the accumulation of Chd protein in vertebral bodies has an essential
requirement for CV2 protein, presumably due to the binding of Chd to
CV2 (Ambrosio et al., 2008).
It could be argued that the accumulation of Chd protein in the
prospective vertebral body might be due to low level transcription of
Chd in this region (which would have to be below detection levels in
the in situ hybridization experiments in Figs. 2D and 3B). However,
because Chd protein is no longer detected in CV2−/− vertebral bodies
(Fig. 5B, D), implicit in this argument is that the presence of CV2
should have the ability to stabilize low levels of Chd protein. At least in
tissue, culture this is not the case. In Fig. 5E, we tested whether CV2
stabilized Chd in Cos7 cells transfected with a full-length CV2
construct (cloned in pCS2) or empty vector. Chd protein was added
to the cells (together with fresh culture medium) and samples
(containing both the culture medium and the cells) analyzed by
western blot at different time points. We found that CV2 over-
expression did not affect Chd stability (Fig. 5E). Although the situation
in tissue culture may differ from that in the vertebral body (since the
translation and proteolysis rates might be different in Cos7 cells), this
result does not support the hypothesis that low levels of Chd
synthesized locally in the prospective vertebral body are stabilized
by CV2. Instead, this experiment is consistent with themodel that CV2
acts as a sink for the ﬂux of Chd from the prospective intervertebral
disc to the prospective vertebral body, in which it accumulates.
The results favor an enhanced sequestration model for the
accumulation of Chd in prospective vertebral body cartilage. To conﬁrm
this, an in vitro experiment using Cos7 cells transfected with a full-
length CV2 construct was carried out (Fig. 5F). Cells transfected with
pCS2 vector or pCS2-CV2 were allowed to secrete CV2 overnight. The
next day, the supernatant was replaced by serum-free medium
containing commercial mouse Chd protein. The amount of Chd bound
by the cell fraction (which included both cells and extracellularmatrix),
or remaining in the supernatant, was determined after 1, 2 or 4 h ofe vertebral bodies, and in cultured cells CV2 serves as a sink for Chd. Immunostainings
e and CV2−/− embryos. (A) Chd antibody staining on a wild-type embryo, showing the
xed in (A). (C) Chd antibody staining on CV2−/− embryo, showing that Chd protein
ws of area boxed in (C). Note that mutation of CV2 prevents Chd accumulation in the
independent experiments). (E) Western blot using an anti-Chd antibody showing that
nant Chd over the course of 24 h. Samples containing culture medium and cell extracts
2 does not affect Chd stability. (F) Western blot analysis of the cell fraction (containing
ression and treated with recombinant mouse Chd. Note that already after 1 h of addition
Fig. 6. Localization and quantiﬁcation of Smad1/5/8 phosphorylation and BMP4 expression in the vertebral column of wild-type and CV2−/− embryos. H&E staining, α-pSmad1/5/
8 andα-BMP4 immunostainings were performed on sagittal sections of 12.5 d.p.c. mouse embryos. (A, D) H&E staining showing a similar cell density in the vertebral bodies (vb) of wild-
type and CV2−/− embryos, even though the size of the vertebral bodies appears reduced and the intervertebral disc (ivd) domain is expanded in the mutant. (B, E) pSmad1/5/8 signal is
nuclear in thevertebral bodies ofwild-type andCV2−/− embryos. (C, F)Quantiﬁcation of the nuclear pSmad1/5/8 signal. Pixels abovebackground level in theoutlined vertebral bodies are
shown in red. Quantiﬁcations of 6 vertebral bodies indicated that CV2−/− cartilage precursors were less stained than in wild-type. (G) Quantiﬁcation showing that the average ratio of
pSmad1/5/8 signal between CV2−/− andwild-typewas 60%. The error bar corresponds to the standard deviation of the ratio of pSmad1/5/8 signal between different individual vertebral
bodies. The wild-type value is 1 as indicated. (H, J) BMP4 antibody staining on wild-type and CV2−/− embryos showing the presence of BMP4 protein in prospective intervertebral discs
(ivd). (I, K)Higherpower viewof thoracic vertebrae 4 (T4)and5 (T5) fromsections shown in (H) and (J), respectively, showing a broadeningof theBMP4expressiondomain in themutant
reﬂecting the widening of the intervertebral disc region.
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of CV2, becoming partially depleted from the culture medium already
after 1 h of incubation (compare lanes 4 and 5). These results support
the view that CV2 can sequester Chd, at least in cell culture.
Does the lack of CV2 cause a change in BMP signaling? Histological
sections of wild-type and CV2mutants were stained with a phospho-
speciﬁc Smad1/5/8 antibody, which provides a measure of BMP
signaling levels. As shown in Figs. 6B and E, the size of the vertebral
body of CV2 mutants was decreased, although the amount of
extracellular matrix and the cellular density was not affected
(Figs. 6A, D). Upon close inspection, phospho-Smad1 levels appeared
lower in CV2 mutants. To quantify this, we used the imageJ softwareand a deconvolution algorithm (Ruifrok and Johnston, 2001) to
determine the average pSmad1/5/8 signal per cell nucleus in three
vertebral bodies, in twodifferent experiments (Figs. 6C, F). Using these
methods, we estimate that the average ratio of pSmad1/5/8 signal
between CV2−/− and wild-type vertebral bodies was 60%, indicating
a 40% decrease in CV2−/− mutants (Fig. 6G). These analyses suggest
that loss of CV2 causes a decrease in BMP signaling in prospective
cartilage, as it does in the Drosophila wing (Ralston and Blair 2005).
We also examined the localization of BMP4 protein. Immunostain-
ing for BMP4 showed that this growth factor was expressed in CV2
mutants (Fig. 6E–H). BMP4 protein was detected in the intervertebral
disc, even though phospho-Smad1/5/8 signaling takes place in the
212 L. Zakin et al. / Developmental Biology 347 (2010) 204–215vertebral body. BMP4 could be relocalized to the vertebral body, but at
levels below detection limits of histochemistry. Interestingly, BMP4
signaling levels are low in the intervertebral discs at this stage,
perhaps because in this tissue BMP4 is coexpressed with its
antagonists Chd, Chdl-1 and Chdl-2 (Fig. 6B, D). The region of BMP4
expression is somewhat wider (Fig. 6H), reﬂecting an expansion of
the intervertebral disc domain in CV2−/− embryos (Fig. 6A, C). TheseFig. 7. TheCV2−/−phenotype invertebral bodycartilage andmodel of the roleofCV2 in theprop
(top panels) and CV2−/− (bottom panels) neonates stained with Alcian Blue (cartilage) and A
magniﬁcations.Note in thevertebral body cartilageofCV2−/− the reduction in size and lossof th
inpart by the lack of facilitated diffusion of Chd/Tsg/BMP4 complexes fromthe intervertebral di
type and CV2−/− developing vertebrae. In thewild-type CV2 is retained in the vertebral body th
in developing cartilage matrix. (D) Chd/BMP4 complexes diffuse from the intervertebral disc
vertebral body, Chd is cleaved by amember of the Tolloidmetalloproteinase family (Tld) allowin
for cartilage development are reached. (E) In CV2−/− vertebrae, Chd/BMP4 complexes do
intervertebral disc, where they are degraded by the action of Tolloid metalloproteinases on Chresults suggest that in the wild-type situation Chd/BMP4 complexes
produced in the prospective intervertebral disc are relocalized to the
vertebral body, presumably bound to Chd. Similar complexes could
also be formed between Chd and BMP2 or Chd and BMP7, since BMP2
and BMP7 also bind Chd and their mRNAs are expressed in the
prospective intervertebral region (Lyons et al., 1995). In this model,
Chd/BMP inhibitory complexes would accumulate in the vertebraler localizationofChd in themousevertebralﬁeld. (A–B') Skeletal preparationsofwild-type
lizarin Red (bone). Tail area is shown at low (left panels) and high (right panels) power
e spool-like shape compared to thewild-type.Wepropose that this phenotype is explained
sc to thevertebral body. (C)Model depicting the localizationof Chd, CV2 andBMP4 inwild-
rough its interactionwith heparin sulfate proteoglycans (HSPGs),which are very abundant
, where they are synthesized, to the vertebral body where they bind to CV2. Once in the
g the release of BMP4 in the vertebral bodies so that the high BMP signaling levels required
not ﬂow from the intervertebral disc to the vertebral body but instead remain in the
d. A, anterior; P, posterior; t5–t11, numbered tail vertebrae.
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released for signaling by Tolloid proteolytic digestion of Chd. In the
absence of CV2, Chd/BMP complexes would fail to concentrate in the
vertebral bodies, resulting in the lowered BMP signaling. This ﬂow of
Chd/BMP complexes in the developing vertebral ﬁeld could provide
an explanation for the defects in vertebral body cartilage formation
observed in CV2 mutant mice (Figs. 7A-B’; Zakin et al., 2008).
The results indicate that in the absence of CV2, Chd fails to relocate
from its site of synthesis in the prospective intervertebral disc to the
prospective vertebral body, helping explain the decrease in BMP
signaling through a reduction in the accumulation of BMP4/Chd
complexes. The accumulation of Chd protein at a distance requires the
presence of CV2.
Discussion
In this study, we showed that both the CV2 and Chd proteins
accumulate in the prospective vertebral body. In situ hybridizations
revealed that the CV2 mRNA is expressed in this region, while BMP4
and Chd mRNAs are expressed in the prospective intervertebral disc.
These results suggest that there is a ﬂow of Chd from its site of
synthesis in the intervertebral disc to the vertebral body, where the
Chd protein accumulates (Figs. 7C, D).
CV2 is required for the accumulation of Chd protein at a distance from its
site of synthesis
CV2 protein is localized in the region where it is synthesized, the
prospective vertebral body (Figs. 3D-F and 7C). This is in agreement
with results inDrosophila in which, although CV2 is a secreted protein,
it has been observed not to diffuse more than two cell diameters from
its site of synthesis, remaining bound to the cell surface via its
interactionwith the glypican surface protein Dally (Serpe et al., 2008).
In the mouse, CV2 was shown to be associated with the extracellular
matrix of cap condensates and collecting ducts of the developing
kidney (Ikeya et al., 2010). In zebraﬁsh, it has also been shown that
CV2 has a heparan sulfate proteoglycan binding site within its vWFd
domain that limits diffusion (Rentzsch et al., 2006). This is particularly
relevant in our case because the extracellular matrix of developing
cartilage tissue, in which CV2 protein accumulates, contains large
amounts of heparan sulfate proteoglycans.
The most remarkable ﬁnding reported in this paper is that Chd
protein accumulates at a considerable distance from its site of
synthesis. Indeed, at 12.5 d.p.c., the embryonic stage chosen for this
study, the distance between the center of the intervertebral disc and
the center of the vertebral body measured between 85.5 μm and
87.9 μm (Fig. 2). This suggests that a ﬂow of Chd over considerable
distances and many cell diameters takes place in vivo (Fig. 3). The
molecular mechanism of this ﬂow was not investigated here.
Because Chd binds to BMPs via its CR domains (Larrain et al.,
2000), and the prospective intervertebral region co-expresses Chd,
BMP4 and Tsg mRNAs (Fig. 2 and Zakin et al., 2008), one expects that
the ﬂow will be comprised not only of Chd but rather of the ternary
complex formed by Chd/Tsg/BMP. The cartilage of the vertebral body,
is the tissue in the vertebral column that requires the highest levels of
BMP signaling in order to develop (Yoon et al., 2005; Retting et al.,
2009). It remains to be determined which BMPmember is responsible
for BMP signaling in the vertebral body. We investigated the
localization of BMP4 protein directly, and found that it is detected
mostly in the intervertebral disc. Presumably the levels of BMP4
ligand required for BMP signaling are too low to be detectable by
immunohistochemistry in the vertebral body. However, nuclear
phospho-Smad1/5/8 signaling was detected mainly in the vertebral
body at this stage, rather than the intervertebral disc where BMP4was
located. Presumably BMP4 was prevented from signaling because it
was complexed to antagonists such as Chd, Chdl-1 and Chdl-2 (Zakinet al., 2008). In the absence of CV2, BMP4 was still expressed, but
Smad1/5/8 signaling levels were reduced in the vertebral body
(Fig. 6).
We propose that in vivo BMP signaling is enhanced by the ﬂux of
Chd/Tsg/BMP4 complexes from intervertebral regions into the
developing vertebral cartilage where BMP4 would be released from
Chd by the action of Tolloid enzymes (Figs. 7C, D). In order for this
mechanism to work, at 12.5 d.p.c., preferential cleavage of Chd/BMP
complexes should take place within the vertebral body, where the
phospho-Smad1/5/8 signal is detected. Of the three Tolloid enzymes
in the mouse, only Tll-1/BMP1, which is expressed in the interverte-
bral disc (Zakin et al., 2008), has a known expression pattern. The
enzyme responsible for cleaving Chd in the future vertebral body
might be one of the other two Tolloids, while Tll-1/BMP1 might be
involved in the BMP signaling that takes place in the intervertebral
body at earlier stages of development (Zakin et al., 2008). Alterna-
tively, Tll-1/BMP1, a secreted protein, may diffuse together with Chd
perhaps in an inactive state. Tolloids provide the rate limiting step in
the Chd pathway, and their activity can be regulated by feedback
inhibitors (Lee et al., 2009).
CV2 is required for the concentration of Chd in the vertebral body
(Figs. 7D, E). Previously, we had determined biochemically that
mouse CV2 can bind Chd and Chd/BMP4 complexes in vitro
(Ambrosio et al., 2008). CV2 is required to trap Chd and Chd/Tsg/
BMP4 complexes ﬂowing towards the vertebral bodies in mouse
embryos. As shown in Fig. 5, in the absence of CV2, Chd and Chd
complexes are no longer detected in the vertebral bodies, and remain
at their site of synthesis These results show that CV2 is required for
the localization of Chd protein in vivo during vertebral
morphogenesis.
Flow of growth factor during patterning
During DrosophilaD-V patterning, the diffusion of BMPs from lateral
regions towards the dorsal amnioserosa in order to achieve peak BMP
signaling has been very well documented. The ﬂow of Sog carrying Dpp
towards the dorsal midline was initially proposed by Holley et al.
(1996). Since then, the ﬂux of Sog/Dpp in Drosophila embryos has been
directly demonstrated. Sog diffuses dorsally from the lateral neuroecto-
derm in which it is produced during gastrulation (Srinivasan et al.,
2002). Later, itwas directly demonstrated that Dpp itself can diffuse, in a
Sog and Tsg dependent way, from ventral regions towards the dorsal
side (Wang and Ferguson, 2005; Shimmi et al., 2005b). Mathematical
modeling has shown that this ﬂow of Sog/BMP makes the dorsal–
ventral morphogen gradient much more robust in its response to
perturbations (Eldar et al., 2002; Shimmi et al., 2005b).
The concept of morphogens was proposed by English mathema-
tician Alan Türing (1952), who suggested that chemical substances
diffusing through a tissue would be able to generate a pattern (Umulis
et al., 2009; Plouhinec and De Robertis, 2007, 2009). The key element
is that morphogens must diffuse in vivo. Examples of morphogens
include the Transforming Growth Factor-β family members (TGF-β)
Activin and Nodal (Gurdon et al., 1994), and ligands of the Epidermal
Growth Factor Receptor in Drosophila (Shilo, 2005). The physical ﬂow
of endogenous morphogens has been directly demonstrated for the
Drosophila Sog/BMP patterning system in early embryos. Even though
existing CV2 loss-of-function mutations are so far compatible with
normal development in Drosophila, CV2 may play an auxiliary role in
the formation of theDrosophilaD-V gradient as CV2 is expressed in the
dorsal side of the Drosophila early embryo (O'Connor et al., 2006;
Serpe et al., 2008).
Flow of growth factors in vertebral column development
We have now demonstrated the accumulation of Chd at a distance
from its site of transcription during the formation of a much later
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the formation of somites, which then form sclerotomes, which in turn
undergo resegmentation, so that the anterior half of one sclerotome
fuses to the posterior half of the one preceding it to form a vertebral
body (Bagnall et al., 1988). This elaborate developmental mechanism
ensures that the tendons and muscles generated by each somite span
adjoining vertebrae. The accumulation of Chd at a distance that has
been reported here at embryonic day 12.5 takes place after somite
resegmentation and is therefore a relatively late occurring event. This
ﬂow of Chd presumably has developmental consequences, since both
the knockout of CV2 and Chd present vertebral column phenotypes
(Bachiller et al., 2000; Zakin et al., 2008). Interestingly, Chd diffusion
appears to be directional, as its accumulation is maximal in the
posterior half of the vertebral body (Fig. 3C).
In the absence of CV2, Chd does not accumulate in vertebral body
cartilage, remaining in the intervertebral disc regionwhere it inhibits
BMP signaling. CV2 and Chd mouse mutants do not have signiﬁcant
genetic interactions (Zakin et al., 2008). We proposed that this may
be due to the expression in the same prospective intervertebral disc,
of Chdl-1 (Nakayama et al., 2001) and Chdl-2 (Nakayama et al., 2004)
in addition to Chd. These proteins are biochemically similar to Chd
andmay compensate for its loss. Furthermore, this redundancy could
also explain why the vertebral column phenotypes are different in
CV2 and Chd mutants. The defects are stronger in CV2−/− embryos
than in Chd−/− embryos; the absence of CV2may affect the localization
of Chd, Chdl-1 and Chdl-2, while only the function of Chordin is affected
in Chd mutants. It remains to be demonstrated whether Chdl-1 and
Chdl-2 alsobindCV2 and relocate to thevertebral body. In addition, Chd,
Chdl-1, and Chdl-2 all require Tsg in order to form efﬁcient complexes
with BMP (Zhang et al., 2007). This may explainwhy Tsg−/− is epistatic
over the CV2 mutant phenotype (Ikeya et al., 2008, 2010; Zakin et al.,
2008), as the function of all BMP antagonists of the Chd familywould be
impaired coordinately. In future, it would be interesting to determine
the localization of Chd, Chdl-1, Chdl-2 and BMP4 in Tsg−/− and CV2−/−;
Tsg−/−mutants. In themeantime,wewouldpredict that the long-range
inhibition of BMP signaling in early stage intervertebral discs observed
previously in CV2 mutants (Zakin et al., 2008) is caused by the
accumulation of all three Chd inhibitors which cannot relocalize to the
vertebral body in the absence of CV2.
Morphogenetic ﬁelds
Since the discovery of morphogenetic ﬁelds by Ross Harrison
(1918), understanding how groups of hundreds or thousands of cells
communicate with each other to form complex anatomical structures
has been a focus of interest for developmental biologists. The
molecular mechanism of long-range communication of the primary
D-V embryonic ﬁeld requires the diffusion of BMPs complexed with
Chd/Sog and Tsg (reviewed in Umulis et al., 2009; Zakin and De
Robertis 2010). Both in Drosophila and Xenopus, this long-range ﬂow
has been directly demonstrated in early embryos (Srinivasan et al.,
2002;Wang and Ferguson 2005; Shimmi et al., 2005a,b; Ben-Zvi et al.,
2008).
During organogenesis stages, many “secondary” cell differentia-
tion ﬁelds are formed, but the molecular mechanism of their
regulation is unclear. Current thinking is that pattern formation in
diverse regenerating systems is mediated through “polar coordinate
positional values” that can be explained in terms of strictly local cell–
cell interactions (e.g., Bryant et al., 1981). However, in this study we
showed that Chordin protein accumulates at a distance from its site of
synthesis suggesting that Chordin diffuses extracellularly over
considerable distances during the differentiation of vertebral carti-
lages. This tissue requires high BMP levels to develop, which are
presumably relocalized as Chd/Tsg/BMP complexes from the inter-
vertebral disc, where they are synthesized, to the vertebral body, in
which they accumulate and are cleaved by Tolloidmetalloproteinases.The Chd-binding protein CV2 is required for the accumulation of Chd
in the extracellular matrix of developing vertebral body cartilage. Chd
emanating from the intervertebral disc does not form a standard
gradient with a high point in the site of origin. Instead, Chd antigen
levels are highest at a distance, indicating that the concentration of
CV2 in cartilage is high enough to act as a sink for Chd complexes. In
future, it will be interesting to investigate whether other secondary
organ-forming morphogenetic ﬁelds also involve the regulated ﬂow
of BMP growth factors and their antagonists across long distances.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2010.08.025.
Acknowledgments
Theauthorswould like to thank JackGreenan for technical assistance,
and members of our laboratory for comments on the manuscript. This
work was supported by the NIH (HD21502-24). E.M.D.R. is an
investigator, and L.Z. a research specialist, of the Howard Hughes
Medical Institute.
References
Ambrosio, A.L., Taelman, V.F., Lee, H.X., Metzinger, C.A., Cofﬁnier, C., De Robertis, E.M.,
2008. Crossveinless-2 Is a BMP feedback inhibitor that binds Chordin/BMP to
regulate Xenopus embryonic patterning. Dev. Cell 15, 248–260.
Bachiller, D., Klingensmith, J., Kemp, C., Belo, J.A., Anderson, R.M., May, S.R., McMahon, J.A.,
McMahon,A.P., Harland, R.M., Rossant, J., DeRobertis, E.M., 2000. Theorganizer factors
Chordin and Noggin are required for mouse forebrain development. Nature 403,
658–661.
Bachiller, D., Klingensmith, J., Shneyder, N., Tran, U., Anderson, R., Rossant, J., De
Robertis, E.M., 2003. The role of Chordin/BMP signals in mammalian pharyngeal
development and DiGeorge syndrome. Development 130, 3567–3578.
Bagnall, K.M., Higgins, S.J., Sanders, E.J., 1988. The contribution made by a single somite
to the vertebral column: experimental evidence in support of resegmentation using
the chick-quail chimaera model. Development 103, 69–85.
Ben-Zvi, D., Shilo, B.Z., Fainsod, A., Barkai, N., 2008. Scaling of the BMP activation
gradient in Xenopus embryos. Nature 453, 1205–1211.
Binnerts, M.E., Wen, X., Cante-Barrett, K., Bright, J., Chen, H.T., Asundi, V., Sattari, P.,
Tang, T., Boyle, B., Funk, W., Rupp, F., 2004. Human crossveinless-2 is a novel
inhibitor of bone morphogenetic proteins. Biochem. Biophys. Res. Commun. 315,
272–280.
Blair, S.S., 2007. Wing vein patterning in Drosophila and the analysis of intercellular
signaling. Annu. Rev. Cell Dev. Biol. 23, 293–319.
Bridges, C., 1920. The mutant crossveinless in Drosophila Melanogaster. PNAS 6, 660–663.
Bryant, S.V., French, V., Bryant, P.J., 1981. Distal regeneration and symmetry. Science
212, 993–1002.
Choi, M., Klingensmith, J., 2009. Chordin is a modiﬁer of tbx1 for the craniofacial
malformations of 22q11 deletion syndrome phenotypes in mouse. PLoS Genet. 5,
e1000395.
Cofﬁnier, C., Tran, U., Larrain, J., De Robertis, E.M., 2001. Neuralin-1 is a novel Chordin-
related molecule expressed in the mouse neural plate. Mech. Dev. 100, 119–122.
Cofﬁnier, C., Ketpura, N., Tran, U., Geissert, D., De Robertis, E.M., 2002. Mouse
Crossveinless-2 is the vertebrate homolog of a Drosophila extracellular regulator of
BMP signaling. Mech. Dev. 119 (Suppl 1), S179–S184.
Coles, E., Christiansen, J., Economou, A., Bronner-Fraser, M., Wilkinson, D.G., 2004. A
vertebrate crossveinless 2 homologue modulates BMP activity and neural crest cell
migration. Development 131, 5309–5317.
Conley, C.A., Silburn, R., Singer, M.A., Ralston, A., Rohwer-Nutter, D., Olson, D.J., Gelbart,
W., Blair, S.S., 2000. Crossveinless 2 contains cysteine-rich domains and is required
for high levels of BMP-like activity during the formation of the cross veins in
Drosophila. Development 127, 3947–3959.
De Robertis, E.M., 2009. Spemann's organizer and the self-regulation of embryonic
ﬁelds. Mech. Dev. 925–941.
Delot, E.C., Shneyder, N., Zhang, H., Bachiller, D., 2007. Abnormal venous and arterial
patterning in Chordin mutants. Dev. Dyn. 236, 2586–2593.
Eivers, E., Fuentealba, L.C., De Robertis, E.M., 2008. Integrating positional information at
the level of Smad1/5/8. Curr. Opin. Genet. Dev. 18, 304–310.
Eldar, A., Dorfman, R., Weiss, D., Ashe, H., Shilo, B.Z., Barkai, N., 2002. Robustness of
the BMP morphogen gradient in Drosophila embryonic patterning. Nature 419,
304–308.
Gurdon, J.B., Harger, P., Mitchell, A., Lemaire, P., 1994. Activin signalling and response to
a morphogen gradient. Nature 371, 487–492.
Harrison, R.G., 1918. Experiments on the development of the fore-limb of Amblystoma,
a self-differentiating equipotential system. J. Exp. Zool. 413–461.
Holley, S.A., Neul, J.L., Attisano, L., Wrana, J.L., Sasai, Y., O'Connor, M.B., De Robertis, E.M.,
Ferguson, E.L., 1996. The Xenopus dorsalizing factor noggin ventralizes Drosophila
embryos by preventing DPP from activating its receptor. Cell 86, 607–617.
Huxley, J.S., De Beer, G.R., 1934. The elements of experimental embryology. Cambridge
University Press, Cambridge.
215L. Zakin et al. / Developmental Biology 347 (2010) 204–215Ikeya, M., Kawada, M., Kiyonari, H., Sasai, N., Nakao, K., Furuta, Y., Sasai, Y., 2006.
Essential pro-Bmp roles of crossveinless 2 in mouse organogenesis. Development
133, 4463–4473.
Ikeya, M., Nosaka, T., Fukushima, K., Kawada, M., Furuta, Y., Kitamura, T., Sasai, Y., 2008.
Twisted gastrulation mutation suppresses skeletal defect phenotypes in Cross-
veinless 2 mutant mice. Mech. Dev. 125, 832–842.
Ikeya, M., Fukushima, K., Kawada, M., Onishi, S., Furuta, Y., Yonemura, S., Kitamura, T.,
Nosaka, T., Sasai, Y., 2010. Cv2, functioningas a pro-BMP factor via twisted gastrulation,
is required for early development of nephron precursors. Dev. Biol. 337, 405–414.
Kelley, R., Ren, R., Pi, X., Wu, Y., Moreno, I., Willis, M., Moser, M., Ross, M., Podkowa, M.,
Attisano, L., Patterson, C., 2009. A concentration-dependent endocytic trap and sink
mechanism converts Bmper from an activator to an inhibitor of Bmp signaling.
J. Cell Biol. 184, 597–609.
Larrain, J., Bachiller, D., Lu, B., Agius, E., Piccolo, S., De Robertis, E.M., 2000. BMP-binding
modules in chordin: a model for signalling regulation in the extracellular space.
Development 127, 821–830.
Larrain, J., Oelgeschlager, M., Ketpura, N.I., Reversade, B., Zakin, L., De Robertis, E.M.,
2001. Proteolytic cleavage of Chordin as a switch for the dual activities of Twisted
gastrulation in BMP signaling. Development 128, 4439–4447.
Lee, H.X., Mendes, F.A., Plouhinec, J.L., De Robertis, E.M., 2009. Enzymatic regulation of
pattern: BMP4 binds CUB domains of Tolloids and inhibits proteinase activity. Genes
Dev. 23, 2551–2562.
Little, S.C., Mullins, M.C., 2004. Twisted gastrulation promotes BMP signaling in
zebraﬁsh dorsal–ventral axial patterning. Development 131, 5825–5835.
Little, S.C., Mullins, M.C., 2006. Extracellular modulation of BMP activity in patterning
the dorsoventral axis. Birth Defects Res. C Embryo Today 78, 224–242.
Lyons, K.M., Hogan, B.L., Robertson, E.J., 1995. Colocalization of BMP 7 and BMP 2 RNAs
suggests that these factors cooperatively mediate tissue interactions during murine
development. Mech. Dev. 50, 71–83.
Nakayama, N., Han, C.E., Scully, S., Nishinakamura, R., He, C., Zeni, L., Yamane, H., Chang,
D., Yu, D., Yokota, T., Wen, D., 2001. A novel chordin-like protein inhibitor for bone
morphogenetic proteins expressed preferentially in mesenchymal cell lineages.
Dev. Biol. 232, 372–387.
Nakayama, N., Han, C.Y., Cam, L., Lee, J.I., Pretorius, J., Fisher, S., Rosenfeld, R., Scully, S.,
Nishinakamura, R., Duryea, D., Van, G., Bolon, B., Yokota, T., Zhang, K., 2004. A novel
chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of
developing cartilage and osteoarthritic joint cartilage. Development 131, 229–240.
Nosaka, T., Morita, S., Kitamura, H., Nakajima, H., Shibata, F., Morikawa, Y., Kataoka, Y.,
Ebihara, Y., Kawashima, T., Itoh, T., Ozaki, K., Senba, E., Tsuji, K., Makishima, F.,
Yoshida, N., Kitamura, T., 2003. Mammalian twisted gastrulation is essential for
skeleto-lymphogenesis. Mol. Cell. Biol. 23, 2969–2980.
O'Connor, M.B., Umulis, D., Othmer, H.G., Blair, S.S., 2006. Shaping BMP morphogen
gradients in the Drosophila embryo and pupal wing. Development 133, 183–193.
Oelgeschläger, M., Larrain, J., Geissert, D., De Robertis, E.M., 2000. The evolutionarily
conserved BMP-binding protein Twisted gastrulation promotes BMP signalling.
Nature 405, 757–763.
Petryk, A., Anderson, R.M., Jarcho, M.P., Leaf, I., Carlson, C.S., Klingensmith, J., Shawlot,
W., O'Connor, M.B., 2004. The mammalian twisted gastrulation gene functions in
foregut and craniofacial development. Dev. Biol. 267, 374–386.
Piccolo, S., Sasai, Y., Lu, B., De Robertis, E.M., 1996. Dorsoventral patterning in Xenopus:
inhibition of ventral signals by direct binding of chordin to BMP-4. Cell 86, 589–598.
Piccolo, S., Agius, E., Lu, B., Goodman, S., Dale, L., De Robertis, E.M., 1997. Cleavage of
Chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the
regulation of Spemann organizer activity. Cell 91, 407–416.
Plouhinec, J.L., De Robertis, E.M., 2007. Systems biology of embryonic morphogens.
Mol. Biosyst. 3, 454–457.
Plouhinec, J.L., De Robertis, E.M., 2009. Systems biology of the self-regulating morphoge-
netic gradient of the Xenopus gastrula. Cold Spring Harbor Perspect Biol 1, a001701.
Ralston, A., Blair, S.S., 2005. Long-range Dpp signaling is regulated to restrict BMP
signaling to a crossvein competent zone. Dev. Biol. 280, 187–200.Rentzsch, F., Zhang, J., Kramer, C., Sebald, W., Hammerschmidt, M., 2006. Crossveinless
2 is an essential positive feedback regulator of Bmp signaling during zebraﬁsh
gastrulation. Development 133, 801–811.
Retting, K.N., Song, B., Yoon, B.S., Lyons, K.M., 2009. BMP canonical Smad signaling
through Smad1 and Smad5 is required for endochondral bone formation.
Development 136, 1093–1104.
Ruifrok, A.C., Johnston, D.A., 2001. Quantiﬁcation of histochemical staining by color
deconvolution. Anal. Quant. Cytol. Histol. 23, 291–299.
Sakuta, H., Suzuki, R., Takahashi, H., Kato, A., Shintani, T., Iemura, S., Yamamoto, T.S.,
Ueno, N., Noda, M., 2001. Ventroptin: a BMP-4 antagonist expressed in a double-
gradient pattern in the retina. Science 293, 111–115.
Scott, I.C., Blitz, I.L., Pappano, W.N., Maas, S.A., Cho, K.W., Greenspan, D.S., 2001.
Homologues of Twisted gastrulation are extracellular cofactors in antagonism of
BMP signalling. Nature 410, 475–478.
Serpe, M., Umulis, D., Ralston, A., Chen, J., Olson, D.J., Avanesov, A., Othmer, H., O'Connor,
M.B., Blair, S.S., 2008. The BMP-binding protein Crossveinless 2 is a short-range,
concentration-dependent, biphasic modulator of BMP signaling in Drosophila. Dev.
Cell 14, 940–953.
Shilo, B.Z., 2005. Regulating the dynamics of EGF receptor signaling in space and time.
Development 132, 4017–4027.
Shimmi, O., Ralston, A., Blair, S.S., O'Connor, M.B., 2005a. The crossveinless gene
encodes a newmember of the Twisted gastrulation family of BMP-binding proteins
which, with Short gastrulation, promotes BMP signaling in the crossveins of the
Drosophila wing. Dev. Biol. 282, 70–83.
Shimmi, O., Umulis, D., Othmer, H., O'Connor, M.B., 2005b. Facilitated transport of a
Dpp/Scw heterodimer by Sog/Tsg leads to robust patterning of the Drosophila
blastoderm embryo. Cell 120, 873–886.
Spemann, H., 1938. Embryonic development and induction. Yale University Press, New
Haven.
Srinivasan, S., Rashka, K.E., Bier, E., 2002. Creation of a Sog morphogen gradient in the
Drosophila embryo. Dev. Cell 2, 91–101.
Türing, A.M., 1952. The chemical basis of morphogenesis. Philo. Trans. Royal Soc.
London 237, 37–72.
Umulis, D., O'Connor, M.B., Blair, S.S., 2009. The extracellular regulation of bone
morphogenetic protein signaling. Development 136, 3715–3728.
Vilmos, P., Sousa-Neves, R., Lukacsovich, T., Marsh, J.L., 2005. crossveinless deﬁnes
a new family of Twisted-gastrulation-like modulators of bone morphogenetic
protein signalling. EMBO Rep. 6, 262–267.
Wang, Y.C., Ferguson, E.L., 2005. Spatial bistability of Dpp-receptor interactions during
Drosophila dorsal–ventral patterning. Nature 434, 229–234.
Winnier, G., Blessing,M., Labosky, P.A., Hogan, B.L., 1995. Bonemorphogenetic protein-4 is
required for mesoderm formation and patterning in the mouse. Genes Dev. 9,
2105–2116.
Yoon, B.S., Ovchinnikov, D.A., Yoshii, I., Mishina, Y., Behringer, R.R., Lyons, K.M., 2005.
Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogen-
esis in vivo. Proc. Natl Acad. Sci. USA 102, 5062–5067.
Zakin, L., De Robertis, E.M., 2004. Inactivation of mouse Twisted gastrulation reveals its
role in promoting Bmp4 activity during forebrain development. Development 131,
413–424.
Zakin, L., De Robertis, E.M., 2010. Extracellular regulation of BMP signaling. Curr. Biol.
20, R89–R92.
Zakin, L., Metzinger, C.A., Chang, E.Y., Cofﬁnier, C., De Robertis, E.M., 2008. Development
of the vertebral morphogenetic ﬁeld in the mouse: interactions between
Crossveinless-2 and Twisted gastrulation. Dev. Biol. 323, 6–18.
Zhang, J.L., Huang, Y., Qiu, L.Y., Nickel, J., Sebald, W., 2007. von Willebrand factor type C
domain-containing proteins regulate bone morphogenetic protein signaling
through different recognition mechanisms. J. Biol. Chem. 282, 20002–20014.
Zhang, J.L., Qiu, L.Y., Kotzsch, A., Weidauer, S., Patterson, L., Hammerschmidt, M., Sebald,
W., Mueller, T.D., 2008. Crystal structure analysis reveals how the Chordin family
member crossveinless 2 blocks BMP-2 receptor binding. Dev. Cell 14, 739–750.
